REACTIVITY OF THE 'HLA-B27' MONOCLONAL ANTIBODY FD705 AGAINST 'RARE' HLA-B*27 PRODUCTS AND ITS LIKELY EPITOPE



J.STREET, E. COATES & C. DARKE

WELSH TRANSPLANTATION AND IMMUNOGENETICS LABORATORY







Introduction

The FITC conjugated 'HLA-B27' monoclonal antibody FD705 (catalogue number B27F50X, One Lambda) is commonly used for routine HLA-B27/B2708 typing by flow cytometry.

We have previously shown that this anybody fails to react with the products of B*27:02 and B*27:08 (1).

We have determined its reactivity against other B*27 allele products and identified its likely epitope. Accordingly this has enabled us to predict its reactivity against other 'rare' B*27 allele products.

Materials and Methods

HLA-B*27 allele products

To further determine the reactivity of FD705 against B27 specificities we tested cells from 52 subjects possessing 14 different B*27 alleles, viz. B*27:01 n=10, B*27:02 n=8, B*27:03 n=1, B*27:04 n=2, B*27:05 n=8, B*27:06 n=1, B*27:07 n=3, B*27:08 n=5, B*27:09 n=1, B*27:10 n=2, B*27:12 n=5, B*27:14 n=2, B*27:17 n=1 B*27:23 n=3.

Flow cytometry testing

Testing used our routine flow cytometry-based B27/B2708 typing protocol (1).

Results

FD705 reactivity

The FD705 monoclonal antibody gave:

- □ Unambiguous positive results against B*27:03, B*27:04, B*27:05, B*27:06, B*27:07, B*27:09, B*27:10, B*27:14 and B*27:17 specificities.
- **Negative** findings against the products of B*27:02, B*27:08, B*27:12 and B*27:23.
- ☐ Variable reactions with B*27:01 products some examples were positive while others were borderline positive or negative.

FD705 epitope

Inspection of HLA class I amino acid sequences suggested that the Bw4/Bw6-related motif **80T 81L 82L 83R** was important for FD705 reactivity.

Thus, all the B*27 products that were clearly FD705 positive possessed this motif, while all those that were negative, with the exception of the B*27:23 specificity, lacked the motif.

This finding with B*27:23 suggests that other residues are involved in the FD705 epitope; a possible candidate being 70K since 70K is possessed by all FD705 positive B27 products, including B*27:01, but is absent from B*27:23.

Importantly, the B*27:01 specificity, solely, has the closely related 80T 81A 82L 83R motif.

The substitution of 81L>A (with different side chain polarity and charge) may be the cause of the unpredictable reactions of B*27:01 products with FD705 due to impaired antibody binding.

Predicted reactivity of FD705

On the basis of identifying the FD705 epitope as including 70K 80T 81L 82L 83R, we predict that of the 84 expressed B*27 proteins (B*27:01-B*27:89) FD705 will react with 61 (72.6%).

It will be negative with 22 (26.2%) and, as seen in this study, it will be 'variable' with the B*27:01 specificity.

Comment

It is clearly important to be aware of an assay's ability to detect the products of 'rare' HLA-B*27 alleles, especially when testing patients from diverse ethnic backgrounds.

Reference

1. Coates, E. & Darke, C. (1998) Routine HLA-B27 typing by flow cytometry - differentiation of the products of HLA- B*2702, B*2705, and B*2708. *European Journal of Immunogenetics* **25**, 29-38.